KEYTRUDA 25 mg/mL concentrate for solution for infusion, favezelimab clinical trials

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

This study is looking at a new combination of treatments, including a medicine called Keytruda, for people with blood cancers. Doctors want to see how safe this new combination is and if it helps to treat these cancers. It's an early-stage study to learn more about the treatment.